Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.
Dulek
Daniel E
DE
Departments of Pediatrics, Vanderbilt University School of Medicine and the Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee, USA. daniel.dulek@vanderbilt.edu
Williams
John V
JV
Creech
C Buddy
CB
Schulert
Alynna K
AK
Frangoul
Haydar A
HA
Domm
Jennifer
J
Denison
Mark R
MR
Chappell
James D
JD
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D057176:Compassionate Use Trials; D016638:Critical Illness; D024882:Drug Resistance, Viral; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000302:isolation & purification*; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology; D007275:Injections, Intravenous; D053139:Oseltamivir / Q000494:pharmacology*; D016896:Treatment Outcome; D019562:Viral Load; D053243:Zanamivir / Q000008:administration & dosage* / Q000009:adverse effects
D000998:Antiviral Agents; D053139:Oseltamivir; D053243:Zanamivir